QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=648DCC623151EB6C1BD56A89A16DA0B0;jsessionid=F643F417C5B131B05933602EC2510AD7;jsessionid=CC440698C953E6D1B5A86C85FDC8691C;jsessionid=F33CBD3B9AC9F919CB11511C00D8B826;jsessionid=76D9ADB202F0159BBF23070C256CDE3F;jsessionid=48D54D049EBCB805C0E1EA85D69B1C56 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. Abnormal open states patterns in the ATXN2 DNA sequence depends on the CAG repeats length.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=648DCC623151EB6C1BD56A89A16DA0B0;jsessionid=F643F417C5B131B05933602EC2510AD7;jsessionid=CC440698C953E6D1B5A86C85FDC8691C;jsessionid=F33CBD3B9AC9F919CB11511C00D8B826;jsessionid=76D9ADB202F0159BBF23070C256CDE3F;jsessionid=48D54D049EBCB805C0E1EA85D69B1C56